Compare ALIT & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALIT | INDP |
|---|---|---|
| Founded | 2017 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 394.4M | 438.4M |
| IPO Year | 2020 | 2021 |
| Metric | ALIT | INDP |
|---|---|---|
| Price | $11.93 | $3.50 |
| Analyst Decision | Hold | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $16.33 | N/A |
| AVG Volume (30 Days) | ★ 686.8K | 329.8K |
| Earning Date | 11-03-2026 | 11-20-2026 |
| Dividend Yield | ★ 6.24% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,262,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.48 | $0.92 |
| 52 Week High | $23.68 | $5.96 |
| Indicator | ALIT | INDP |
|---|---|---|
| Relative Strength Index (RSI) | 68.27 | 56.14 |
| Support Level | $8.20 | $2.05 |
| Resistance Level | $13.21 | $3.84 |
| Average True Range (ATR) | 1.08 | 0.31 |
| MACD | 0.44 | 0.02 |
| Stochastic Oscillator | 54.46 | 78.10 |
Alight Inc is a technology-enabled services company delivering human capital management solutions to many complex organizations. This includes the implementation and administration of employee benefits (e.g., health, wealth, and leave benefits) solutions, which currently operate under one reportable segment, Employer Solutions. The Employer Solutions segment is driven by the Alight Worklife platform, and includes integrated benefits administration, healthcare navigation, financial well-being, leave of absence management, and retiree healthcare. Geographically, the company generates the majority of its revenue from the United States.
Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.